Related Experiment Video
Updated: Apr 24, 2026
Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Laura G Estévez1, Ana Suarez-Gauthier2, Elena García3
1Breast Cancer Program, Centro Integral Oncológico Clara Campal, C/Oña 10, Madrid, 28050, Spain. lestevez@hmhospitales.com.
Introduction:
Human epidermal growth factor receptor 2 (HER2) amplification is frequent in ductal carcinoma in situ (DCIS) of the breast and is associated with poorly differentiated tumors and adverse prognosis features. This study aimed to determine the molecular effects of the HER2 inhibitor lapatinib in patients with HER2 positive DCIS.
Methods:
Patients with HER2 positive DCIS received 1,500 mg daily of lapatinib for four consecutive weeks prior to surgical resection. Magnetic resonance imaging (MRI) was used to determine changes in tumor volume. The molecular effects of lapatinib on HER2 signaling (PI3K/AKT and RAS/MAPK pathways), cell proliferation (Ki67 and p27) and apoptosis (TUNEL) were determined in pre and post-lapatinib treatment samples.
Results:
A total of 20 patients were included. Lapatinib was well tolerated with only minor and transient side effects. The agent effectively modulated HER2 signaling decreasing significantly pHER2 and pERK1 expression, together with a decrease in tumor size evaluated by MRI. There was no evidence of changes in Ki67.
Conclusions:
Four weeks of neoadjuvant lapatinib in patients with HER2-positive DCIS resulted in inhibition of HER2 and RAS/MAPK signaling pathway.
Trial Registration:
2008-004492-21 (Registered June 25th 2008).
Insights
Neoadjuvant lapatinib effectively inhibited HER2 and RAS/MAPK signaling in patients with HER2-positive ductal carcinoma in situ (DCIS), reducing tumor size. This targeted therapy shows promise for HER2-positive breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2 amplification is common in ductal carcinoma in situ (DCIS) and linked to poor prognosis.
- HER2-positive DCIS requires targeted therapeutic strategies.
- Understanding molecular effects of HER2 inhibitors in DCIS is crucial.
Purpose of the Study:
- To evaluate the molecular impact of lapatinib on HER2-positive DCIS.
- To assess changes in HER2 signaling pathways, proliferation, and apoptosis.
- To determine the effect of lapatinib on tumor volume.
Main Methods:
- 20 patients with HER2-positive DCIS received 1500 mg daily lapatinib for 4 weeks pre-surgery.
- Tumor volume changes were assessed using MRI.
- Molecular markers of HER2 signaling (pHER2, pERK1), proliferation (Ki67, p27), and apoptosis (TUNEL) were analyzed.
Main Results:
- Lapatinib was well-tolerated with minimal side effects.
- Significant decrease in pHER2 and pERK1 expression was observed.
- MRI showed a reduction in tumor size, but no significant change in Ki67 was detected.
Conclusions:
- Four weeks of neoadjuvant lapatinib inhibits HER2 and RAS/MAPK signaling in HER2-positive DCIS.
- Lapatinib demonstrates potential as a neoadjuvant treatment for HER2-positive DCIS.
- Targeted inhibition of HER2 signaling pathways is achievable in DCIS.
More Related Videos
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017